Showing 941-950 of 23043 results for "".
How to Apply Social Networks in Social Learning for Healthcare Teams
https://reachmd.com/programs/lifelong-learning/how-to-apply-social-networks-in-social-learning-for-healthcare-teams/10016/How can using Facebook and other social media networks promote social learning in your healthcare team?Universal MRSA Screening Among Hospital Patients
https://reachmd.com/programs/focus-on-public-health-policy/universal-mrsa-screening-among-hospital-patients/3708/Methicillin-resistant Staphylococcus aureus (MRSA) is responsible for eight percent of all hospital-acquired infections in the United States, leading to upwards of 20,000 deaths per year. Several states have passed legislation mandating screening of hospital patients for MRSA. How effective are thesLeveraging Clinical Data: HER2-Targeted ADCs in Second-Line and Beyond MBC
https://reachmd.com/programs/cme/leveraging-clinical-data-her2-targeted-adcs-in-second-line-and-beyond-mbc/29946/What’s the latest on managing HER2-expressing MBC with brain metastasis? Join our experts and learn about the most recent treatment strategies.Less Medicine, More Health: 7 Assumptions That Drive Too Much Medical Care
https://reachmd.com/programs/book-club/less-medicine-more-health-7-assumptions-drive-too-much-medical-care/9504/Dr. H. Gilbert Welch explains why offering too much health care can actually do more harm than good.Amivantamab Monotherapy or in Combination With Paclitaxel in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: OrigAMI-4 Study Results
https://reachmd.com/clinical-practice/oncology-hematology/amivantamab-monotherapy-or-in-combination-with-paclitaxel-in-previously-treated-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-origami-4-study-results/39780/In the phase 1b/2 OrigAMI-4 trial, amivantamab alone or with paclitaxel showed strong and durable responses in previously treated recurrent or metastatic HNSCC.Advancing MS Care: Diagnostic Clarity, Early Action, and Patient-Centered Treatment
https://reachmd.com/programs/frontlines-multiple-sclerosis/advancing-ms-care-diagnostic-clarity-early-action-and-patient-centered-treatment/36391/With the latest revisions to the McDonald criteria and new therapies on the horizon, multiple sclerosis (MS) care is entering a pivotal phase. In this expert-led discussion, Dr. Gates Colbert sits down with Dr. Tirisham Gyang to unpack how emerging diagnostic tools, earlier intervention strategies,Amalia's Tale: A Poor Peasant, an Ambitious Attorney, and a Fight for Justice
https://reachmd.com/programs/clinicians-roundtable/amalias-tale-a-poor-peasant-an-ambitious-attorney-and-a-fight-for-justice/2484/We all know that sometimes the answers to today’s problems can be found in the past. Our guest today will take us to 19th century Italy where we will have a glimpse into a dark page of social and medical history. At one time, up to 10% of European men had syphilis – its victims were rumored to incluAddressing Breast Cancer's High Recurrence Rates: The Breast Cancer Translational Center of Excellence (TCE)
https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/addressing-breast-cancers-high-recurrence-rates-breast-cancer-translational-center-excellence-tce/7981/ReachMD takes a closer look at Penn Medicine’s Breast Cancer Translational Center of Excellence (TCE), known as the 2-PREVENT TCE.Medical Marketing One Year Later: Lessons Learned After 60 Episodes
https://reachmd.com/programs/healthcares-prescription-web-social-marketing/medical-marketing-one-year-later-lessons-learned-after-60-episodes/9836/Russ and Randy reflect on the milestone of their first year of podcasts to share some lessons learned on HCP Internet marketing.Impact of Finerenone on eGFR Slope by Baseline Albuminuria in FINEARTS-HF
https://reachmd.com/cme/ACC-2025-nsMRA-HF/impact-of-finerenone-on-egfr-slope-by-baseline-albuminuria-in-finearts-hf/35846/Dr. Finnian McCausland shares new data from ERA 2025 showing finerenone slows eGFR decline across albuminuria levels in patients with HFmrEF/HFpEF.